Oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Type (Breast Cancer, Melanoma Cancer, Colorectal Cancer, Prostate Cancer, Lung Cancer, Others), By Study (Interventional studies, Observational studies, Expanded access studies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Oncology Clinical Trials Market Size & Growth Analysis

The global oncology clinical trials market size was valued at USD 18.55 billion in 2025 and is projected to grow from USD 20.11 billion in 2026 to USD 38.37 billion by 2034, registering a CAGR of 8.41% during the forecast period from 2026 to 2034. North America dominated the oncology clinical trials market with a market share of 47.92% in 2025.

The global market encompasses studies focused on evaluating innovative cancer therapeutics and treatment approaches across multiple cancer types, including breast, melanoma, colorectal, prostate, lung, and other malignancies. These trials span across different phases, such as Phase I, Phase II, Phase III, and Phase IV, each playing a critical role from initial safety assessment to post-marketing evaluation. Based on study design, oncology clinical trials are classified into interventional, observational, and expanded access studies, aimed at assessing new therapies, monitoring outcomes, and providing investigational treatments. The market ecosystem comprises pharmaceutical and biotechnology companies, clinical research organizations, academic institutes, and regulatory agencies that collectively drive clinical development, streamline patient recruitment, and support the advancement of targeted, immune oncology, and combination therapies to improve cancer treatment outcomes.

Phase Insights

The Phase I segment is dominated the market in 2025 with a revenue share of 35.26%, owing to the increasing focus on early stage drug development, the rising number of novel oncology compounds entering clinical evaluation, and the need to assess safety and dosage in humans.

The Phase III is estimated to register the fastest CAGR of 9.23% during the forecast period, owing to the fact that phase III trials are the costliest as they involve a large number of participants. These trials also include long term safety studies conducted for regulatory approval and post marketing commitments.

Request Customizationto receive a tailored report.

Type Insights

The prostate cancer segment is anticipated to grow at a CAGR of 9.12% during 2026-2034. This growth is attributed to the rising prevalence of prostate cancer among aging populations, increasing awareness and early detection programs, and the development of innovative targeted therapies.

The breast cancer segment dominated the market, with a revenue share of 17.23%, owing to strong focus on early detection and personalized therapies. Continuous advancements in hormone, targeted, and immunotherapies drive extensive research activity. Moreover, substantial funding and awareness initiatives further accelerate clinical development in this segment.

Study Insights

The interventional studies segment dominated the market in 2025, with a revenue share of 75.63%. Interventional studies remained the backbone of oncology trials as they directly tested experimental therapies in controlled settings. Their ability to generate strong evidence on safety and efficacy made them the preferred approach for sponsors and regulators, driving continuous growth and innovation in the oncology clinical trials market.

The observational studies are estimated to register the fastest CAGR during the forecast period, due to the growing emphasis on long-term patient outcome tracking, and post-marketing surveillance. These studies provide valuable insights into treatment effectiveness, safety, and patient quality of life beyond controlled trial settings.

Speak to an Analystto discuss market opportunities.

Regional Analysis

The North America region dominated the market with a revenue share of 47.92% in 2025. North America’s market grew strongly because of the integration of electronic health records, biobanks, and population genomics projects that streamlined trial recruitment and monitoring. In the U.S., programs like NIH’s All of Us, which returned genomic results to over 100,000 participants by 2024, expanded trial-ready databases and enhanced personalized trial designs. This integration reduced patient identification barriers, improved trial diversity, and helped sponsors run oncology trials with greater speed and precision.

The U.S. market is anticipated to witness significant market growth owing to the government’s Cancer Moonshot program, which aimed to speed up cancer research by improving access to clinical trials and funding new trial models. In 2024, the NCI expanded community-based trial networks, making oncology studies available in more local and underserved areas. This helped improve trial participation and gave sponsors the chance to test therapies in real-world, diverse patient settings.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Market Insights

The Asia Pacific region is the fastest-growing region with a CAGR of 9.52% during the forecast timeframe, owing to strong government support for precision medicine programs and heavy investments in genomics infrastructure. Countries like China, Japan, and South Korea improved access and affordability of cancer testing and trial participation. These initiatives encouraged more oncology trials across the region.

The Chinese market is anticipated to witness significant market growth owing to the regulatory flexibility that allows the use of real-world evidence (RWE) to support drug approvals. In 2024, the NMPA approved several oncology drugs using RWE from pilot zones like Hainan Boao. This approach encouraged more sponsors to run oncology trials in China.

Europe Market Insights

In Europe, the market is witnessing steady growth driven by continuous advancements in healthcare infrastructure and patient care standards. Ongoing updates in diagnostic and treatment protocols across European nations have fostered the adoption of innovative therapeutic approaches. Several cancer centers across the region upgraded their facilities, aligning with new standards of cancer care. These enhancements have accelerated demand for novel oncology drugs and advanced clinical research, thereby propelling the growth of the oncology clinical trials market in Europe.

In Spain, the oncology clinical trials market is expanding significantly, supported by the rising cancer burden across age groups. As shown in the graph, cancer risk increases markedly with age, reaching 47.8% among men and 32.7% among women aged 80–84. This escalating incidence underscores the urgent need for advanced therapeutic interventions and the continued development of innovative oncology treatments through clinical research.

Middle East and Africa Market Insights

The oncology clinical trials market in the Middle East and Africa is witnessing steady growth driven by rapid advancements in cancer care infrastructure and accessibility to oncology drugs. Countries such as Saudi Arabia, the UAE, and South Africa are investing heavily in specialized cancer centers to enhance cancer diagnosis, treatment, and research capabilities.

In South Africa, the oncology clinical trials market is gaining traction with growing initiatives to enhance childhood cancer care. The implementation of the Paediatric Oncology Facility Integrated Local Evolution (ProFILE) tool is enabling systematic evaluation and improvement of pediatric oncology services nationwide. As cancer care delivery becomes more structured, equitable, and accessible, the rising demand for innovative oncology drugs and therapies for childhood cancers is expected to significantly contribute to the growth of South Africa’s market.

Latin America Market Insights

Across Latin America, the market is experiencing strong growth driven by the widespread adoption of national cancer screening initiatives. Countries such as Brazil, Mexico, and Argentina are implementing large-scale programs targeting breast, cervical, and colorectal cancers to enhance early detection and improve treatment outcomes. Government-supported efforts, including Brazil’s Unified Health System (SUS), are expanding access to preventive healthcare and promoting timely interventions, thereby increasing the demand for advanced diagnostics, oncology drugs, and clinical research in the region.

Mexico is emerging as a key hub for oncology clinical trials, supported by major investments from local pharmaceutical companies. The announcement by four Mexican pharmaceutical companies, Kener, Genbio, Neolpharma, and Neolsym, to invest over USD 722 million presents a significant opportunity for the country’s oncology clinical trials market. Amid chronic shortages of essential cancer medications and limited access to innovative therapies, this investment supports the federal government’s Plan México initiative, which aims to boost domestic pharmaceutical production and research capacity. By strengthening local capabilities for drug development and clinical research, these investments accelerated trial initiation, improved patient enrollment, and enhanced the availability of innovative oncology therapies, fostering a more dynamic and resilient clinical trials ecosystem in the country.

Competitive Landscape

The global market is highly fragmented with the presence of numerous multinational pharmaceutical companies, contract research organizations (CROs), and emerging biotech firms actively engaged in developing innovative therapies.

OncoNova Therapeutics, Inc.: An emerging market player

OncoNova Therapeutics, Inc., is an emerging player in the global market, focusing on novel small-molecule therapeutics targeting hematologic malignancies and solid tumors.

• In April 2025,OncoNova Therapeutics, Inc. initiated Phase II clinical trials for its lead candidate, ONC-123, a targeted therapy designed to inhibit cyclin-dependent kinases in patients with relapsed or refractory acute myeloid leukemia (AML).

List of Key and Emerging Players in Oncology Clinical Trials Market